NASH: Evaluating Emerging Diagnostic and Treatment Strategies

In this on-demand Webcast, expert faculty review the latest diagnostic resources, emerging and investigational therapies, and strategies for improving the care of patients with NASH.
Stephen A. Harrison, MD, COL (Ret.), FAASLD
Program Director
Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
Mary E. Rinella, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: December 23, 2016 Expiration: December 22, 2017

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients who should undergo assessment for NAFLD/NASH
  • Utilize invasive and noninvasive tools to diagnose NASH and predict patient outcomes
  • Apply current best practices in the management of NASH, including lifestyle changes and pharmacologic therapies
  • Counsel patients on progress of investigational therapies for NASH, including mechanisms of action, safety, and hepatic efficacy outcomes

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Stephen A. Harrison, MD, COL (Ret.), FAASLD

Visiting Professor of Hepatology
Radcliffe Department of Medicine
University of Oxford
Oxford, United Kingdom

Stephen A. Harrison, MD, COL (Ret.), FAASLD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, the Chronic Liver Disease Foundation, FibroGen, Genfit, Intercept, Medivation, Merck, NGM Biopharmaceuticals, and Pfizer; has received fees for non-CME/CE services from AbbVie, Alexion, Gilead Sciences, and Merck; and funds for research support paid to his institution from Bristol-Myers Squibb, Conatus, Galectin, Galmed, Gilead Sciences, Immuron, Intercept, Madrigal, Merck, NGM Biopharmaceuticals, and Tobira.

Faculty

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP

Professor of Experimental Hepatology 
Consultant Hepatologist
Institute of Cellular Medicine
Newcastle University
Newcastle Upon Tyne, United Kingdom

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP, has disclosed that he has received consulting fees paid to his institution from Acuitas Medical, Genfit, Intercept, Inventiva, Janssen, Lilly, NewGene, Pfizer, Raptor Pharmaceuticals, and Tobira and funds for research support paid to his institution from AbbVie and GlaxoSmithKline.

Mary E. Rinella, MD

Associate Professor of Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Mary E. Rinella, MD, has disclosed that she has received consulting fees from Amarin, BioPharma, Echosens, Enanta, Immuron, Intercept, NGM Biopharmaceuticals, and NuSirt.

Staff

Monique Carasso, MSN, ANP-C

Staff Faculty
Adult Nurse Practitioner
Division of Medicine, Hepatology
Weill Cornell Medical College
New York, New York

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers involved in the care of patients with NASH.

Goal

The goal of this activity is to improve participants’ confidence and competence in diagnosing and managing patients with NASH, as well as to improve participants’ knowledge of emerging and investigational therapies for the management of NASH.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 23, 2016, through December 22, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CCO slides from Martin Abrahamson, MD, and Anne Peters, MD, on GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence

Martin J. Abrahamson, MD Anne Peters, MD Released: January 17, 2020

Slides from CCO and John Russell, MD, on GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence

John J. Russell, MD Released: December 23, 2019

CME: Type 2 diabetes management: Dr. Veronica K. Piziak on NPH, regular insulin, switching to avoid hypoglycemia/reduce CV risk in T2DM

Veronica K. Piziak, MD, PhD, FACP
Program Director
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: January 11, 2019 Expiration: January 10, 2020

Dr. Kenneth Cusi summarizes some of the most important data from recent studies in patients at high risk for NASH/NAFLD.

Kenneth Cusi, MD, FACP, FACE
Program Director
Released: December 13, 2018

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an educational grant from
Intercept Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?